参考文献
1.Crettola S,Petrovicb N,Murraya M.Pharmacogenetics of phaseⅠ and phaseⅡdrug metabolism current pharmaceutical design,2010,16,204-219
2.Evans WE,RellingMV.Pharmacogenomics:Translating Functional Genomics into Rational Therapeutics.Science,1999,286:487-491
3.Ginsburg GS,Willard HF.Genomic and personalized medicine:foundations and applications.Transl Res.2009;154:277-87
4.Hall IP,Pirmohamed M.Pharmacogenetics.New York:Taylor and Fracis Group,2006
5.Kalow W.Pharmacogenetics of Drug Metabolism.New York:Pergamon Press,1992
6.Weber WW.Pharmacogenetics.New York:OxfordUniversity Press,1997
7.Zhou HH.Racial differences in drug response:Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites.N Eng J Med 1989,320:565-570
8.Wadelius M,Sörlin K,Wallerman O,et al.Warfarin sensitivity related to CYP2C9,CYP3A5,ABCB1(MDR1)and other factors.The pharmacogenomics journal,2004,4(1):40-48
9.Wadelius M,Chen LY,Downes K,et al.Common VKORC1 and GGCX polymorphisms associated with warfarin dose.The pharmacogenomics journal,2005,5(4):262-270
10.Lindh JD,Holm L,Andersson ML,et al.Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis.European journal of clinical pharmacology,2009,65(4):365-375
11.周宏灏.遗传药理学.北京:人民军医出版社,2003